Additionally, a phase 1b/2 trial (NCT04985604) is investigating tovorafenib (BRAF/CRAF inhibitor, DayOne) and pimasertib (MEK1/2 inhibitor, Merck KGaA) for solid tumors, including NSCLC harboring MAPK pathway mutations35. Here, MAP2K1 is linked to non-small cell lung carcinoma.